{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "30",
                "@year": "2023",
                "@timestamp": "2023-06-30T02:47:29.000029-04:00",
                "@month": "06"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2022",
                "@month": "01"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Adult Bone Marrow Transplantation"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "103509438"
                            },
                            "state": "NY",
                            "ce:source-text": "Adult Bone Marrow Transplantation, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States",
                            "@dptid": "103509438"
                        },
                        "author": [
                            {
                                "ce:given-name": "Kitsada",
                                "preferred-name": {
                                    "ce:given-name": "Kitsada",
                                    "ce:initials": "K.",
                                    "ce:surname": "Wudhikarn",
                                    "ce:indexed-name": "Wudhikarn K."
                                },
                                "@seq": "1",
                                "ce:initials": "K.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Wudhikarn",
                                "@auid": "37091810400",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            {
                                "ce:given-name": "Ana Alarcón",
                                "preferred-name": {
                                    "ce:given-name": "Ana Alarcón",
                                    "ce:initials": "A.A.",
                                    "ce:surname": "Tomás",
                                    "ce:indexed-name": "Tomás A.A."
                                },
                                "@seq": "2",
                                "ce:initials": "A.A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Tomás",
                                "@auid": "57216155516",
                                "ce:indexed-name": "Tomas A.A."
                            },
                            {
                                "ce:given-name": "Miguel-Angel",
                                "preferred-name": {
                                    "ce:given-name": "Miguel Angel",
                                    "ce:initials": "M.A.",
                                    "ce:surname": "Perales",
                                    "ce:indexed-name": "Perales M.A."
                                },
                                "@seq": "3",
                                "ce:initials": "M.-A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Perales",
                                "@auid": "6701893624",
                                "ce:indexed-name": "Perales M.-A."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Hematology and Research Unit in Translational Hematology"},
                                {"$": "Department of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "126210793"
                                },
                                {"@afid": "60028190"}
                            ],
                            "ce:source-text": "Division of Hematology and Research Unit in Translational Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "126210793"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Spain",
                            "@afid": "60000130",
                            "@country": "esp",
                            "city": "Murcia",
                            "organization": {"$": "University of Murcia"},
                            "affiliation-id": {"@afid": "60000130"},
                            "ce:source-text": "PhD Program in Signals Integration and Modulation in Biomedicine, Cell Therapy and Translational Medicine, University of Murcia, Murcia, Spain"
                        },
                        "author": [{
                            "ce:given-name": "Ana Alarcón",
                            "preferred-name": {
                                "ce:given-name": "Ana Alarcón",
                                "ce:initials": "A.A.",
                                "ce:surname": "Tomás",
                                "ce:indexed-name": "Tomás A.A."
                            },
                            "@seq": "2",
                            "ce:initials": "A.A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Tomás",
                            "@auid": "57216155516",
                            "ce:indexed-name": "Tomas A.A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Pathology and Laboratory Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "113431398"
                            },
                            "state": "NY",
                            "ce:source-text": "Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States",
                            "@dptid": "113431398"
                        },
                        "author": [{
                            "ce:given-name": "Kazunori",
                            "preferred-name": {
                                "ce:given-name": "Kazunori",
                                "ce:initials": "K.",
                                "ce:surname": "Murata",
                                "ce:indexed-name": "Murata K."
                            },
                            "@seq": "4",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Murata",
                            "@auid": "7403723230",
                            "ce:indexed-name": "Murata K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007997",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Weil Cornell College of Medicine"}
                            ],
                            "affiliation-id": {
                                "@afid": "60007997",
                                "@dptid": "112748380"
                            },
                            "state": "NY",
                            "ce:source-text": "Department of Medicine, Weil Cornell College of Medicine, New York, NY, United States",
                            "@dptid": "112748380"
                        },
                        "author": [{
                            "ce:given-name": "Miguel-Angel",
                            "preferred-name": {
                                "ce:given-name": "Miguel Angel",
                                "ce:initials": "M.A.",
                                "ce:surname": "Perales",
                                "ce:indexed-name": "Perales M.A."
                            },
                            "@seq": "3",
                            "ce:initials": "M.-A.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Perales",
                            "@auid": "6701893624",
                            "ce:indexed-name": "Perales M.-A."
                        }]
                    }
                ],
                "citation-title": "Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers",
                "abstracts": "© 2022 Elsevier Inc. All rights reserved.Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment armamentarium of relapsed/refractory hematologic malignancies, enabling high response rates, and potential cure. Despite these impressive antitumor effects, many patients experience relapse or fail to respond after receiving CAR T cells. There are also several unique side effects associated with morbidity and mortality, including immune-mediated phenomena, prolonged cytopenias, B-cell aplasia, and hypogammaglobulinemia. Several studies have explored predictive biomarkers to identify patients at risk of treatment failure or adverse events. A biomarker-based approach to CAR T-cell treatment may improve patient selection by identifying risk factors for nonresponders and for severe toxicities, as well as help researchers identify targets for novel CAR T-cell products.",
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "Biomarkers",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "CAR T cell",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "chimeric antigen receptor T cell",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "hematologic malignancy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ch"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "Cancer Biomarkers: Clinical Aspects and Laboratory Determ.",
                    "website": {"ce:e-address": {
                        "$": "https://www.sciencedirect.com/book/9780128243022",
                        "@type": "email"
                    }},
                    "@country": "gbr",
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "volisspag": {"pagerange": {
                        "@first": "245",
                        "@last": "281"
                    }},
                    "@type": "b",
                    "publicationyear": {"@first": "2022"},
                    "isbn": [
                        {
                            "@level": "volume",
                            "$": "9780128243022",
                            "@type": "electronic",
                            "@length": "13"
                        },
                        {
                            "@level": "volume",
                            "$": "9780128243039",
                            "@type": "print",
                            "@length": "13"
                        }
                    ],
                    "publisher": {"publishername": "Elsevier"},
                    "sourcetitle": "Cancer Biomarkers: Clinical Aspects and Laboratory Determination",
                    "@srcid": "21101107507",
                    "publicationdate": {
                        "month": "01",
                        "year": "2022",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "1 January 2022"
                        },
                        "day": "01"
                    }
                },
                "enhancement": {"classificationgroup": {"classifications": [
                    {
                        "@type": "ASJC",
                        "classification": [
                            {"$": "1100"},
                            {"$": "1300"}
                        ]
                    },
                    {
                        "@type": "SUBJABBR",
                        "classification": [
                            {"$": "AGRI"},
                            {"$": "BIOC"}
                        ]
                    }
                ]}}
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "SCOPUS"},
                    {"$": "SNBOOK"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "19",
                    "@year": "2022",
                    "@timestamp": "BST 09:50:43",
                    "@month": "09"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "639013334",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "942884507",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20223224960",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2022249394",
                            "@idtype": "SNBOOK"
                        },
                        {
                            "$": "20222000517609",
                            "@idtype": "TPB-ID"
                        },
                        {
                            "$": "20221001586827",
                            "@idtype": "VTW-CAR-ID"
                        },
                        {
                            "$": "85137915823",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85137915823",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:doi": "10.1016/B978-0-12-824302-2.00012-6"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "97",
                "reference": [
                    {
                        "ref-fulltext": "June C.H., O\u2019Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20131365. doi:10.1126/science.aar6711",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1126/science.aar6711",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CAR T cell immunotherapy for human cancer"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85046048878",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "359",
                                    "@issue": "6382"
                                },
                                "pagerange": {
                                    "@first": "1361",
                                    "@last": "1365"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.H.",
                                    "@_fa": "true",
                                    "ce:surname": "June",
                                    "ce:indexed-name": "June C.H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.S.",
                                    "@_fa": "true",
                                    "ce:surname": "O\u2019Connor",
                                    "ce:indexed-name": "O'Connor R.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "O.U.",
                                    "@_fa": "true",
                                    "ce:surname": "Kawalekar",
                                    "ce:indexed-name": "Kawalekar O.U."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Ghassemi",
                                    "ce:indexed-name": "Ghassemi S."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "M.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Milone",
                                    "ce:indexed-name": "Milone M.C."
                                }
                            ]},
                            "ref-sourcetitle": "Science"
                        },
                        "ce:source-text": "June C.H., O\u2019Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20131365. doi:10.1126/science.aar6711"
                    },
                    {
                        "ref-fulltext": "Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(5):332. doi:10.1038/d41573-021-00063-1",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/d41573-021-00063-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "FDA approves first BCMA-targeted CAR-T cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85104059490",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "5"
                                },
                                "pagerange": {"@first": "332"}
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "ce:surname": "Mullard",
                                "ce:indexed-name": "Mullard A."
                            }]},
                            "ref-sourcetitle": "Nat Rev Drug Discov"
                        },
                        "ce:source-text": "Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(5):332. doi:10.1038/d41573-021-00063-1"
                    },
                    {
                        "ref-fulltext": "Munshi N.C., Anderson L.D., Jr., Shah N., et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u2013716. doi:10.1056/NEJMoa2024850",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa2024850",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Idecabtagene vicleucel in relapsed and refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85101643459",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "384",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "705",
                                    "@last": "716"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Munshi",
                                        "ce:indexed-name": "Munshi N.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Anderson",
                                        "ce:suffix": "Jr.",
                                        "ce:indexed-name": "Anderson L.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Munshi N.C., Anderson L.D., Jr., Shah N., et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u2013716. doi:10.1056/NEJMoa2024850"
                    },
                    {
                        "ref-fulltext": "Neelapu S.S., Locke F.L., Bartlett N.L., et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u20132544. doi:10.1056/NEJMoa1707447",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1707447",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85040170618",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "377",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "2531",
                                    "@last": "2544"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bartlett",
                                        "ce:indexed-name": "Bartlett N.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Neelapu S.S., Locke F.L., Bartlett N.L., et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u20132544. doi:10.1056/NEJMoa1707447"
                    },
                    {
                        "ref-fulltext": "Schuster S.J., Bishop M.R., Tam C.S., et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. doi:10.1056/NEJMoa1804980",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1804980",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85058995720",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "45",
                                    "@last": "56"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schuster",
                                        "ce:indexed-name": "Schuster S.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Schuster S.J., Bishop M.R., Tam C.S., et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. doi:10.1056/NEJMoa1804980"
                    },
                    {
                        "ref-fulltext": "Abramson J.S., Palomba M.L., Gordon L.I., et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u2013852. doi:10.1016/S0140-6736(20)31366-0",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(20)31366-0",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85090978508",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "396",
                                    "@issue": "10254"
                                },
                                "pagerange": {
                                    "@first": "839",
                                    "@last": "852"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Gordon",
                                        "ce:indexed-name": "Gordon L.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Abramson J.S., Palomba M.L., Gordon L.I., et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u2013852. doi:10.1016/S0140-6736(20)31366-0"
                    },
                    {
                        "ref-fulltext": "Jacobson C., Chavez J.C., Sehgal A.R., et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020; 136(Supplement 1):40\u201341. doi:10.1182/blood-2020-136834",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2020-136834",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85100265083",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "136"},
                                "pagerange": {
                                    "@first": "40",
                                    "@last": "41"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chavez",
                                        "ce:indexed-name": "Chavez J.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Sehgal",
                                        "ce:indexed-name": "Sehgal A.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood."
                        },
                        "ce:source-text": "Jacobson C., Chavez J.C., Sehgal A.R., et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020; 136(Supplement 1):40\u201341. doi:10.1182/blood-2020-136834"
                    },
                    {
                        "ref-fulltext": "Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u20131342. doi:10.1056/NEJMoa1914347",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1914347",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082856912",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "382",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "1331",
                                    "@last": "1342"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Munoz",
                                        "ce:indexed-name": "Munoz J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goy",
                                        "ce:indexed-name": "Goy A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u20131342. doi:10.1056/NEJMoa1914347"
                    },
                    {
                        "ref-fulltext": "Shah B.D., Ghobadi A., Oluwole O.O., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. doi:10.1016/S0140-6736(21)01222-8",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(21)01222-8",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85108290376",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "398",
                                    "@issue": "10299"
                                },
                                "pagerange": {
                                    "@first": "491",
                                    "@last": "502"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah B.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "O.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole O.O."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Shah B.D., Ghobadi A., Oluwole O.O., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. doi:10.1016/S0140-6736(21)01222-8"
                    },
                    {
                        "ref-fulltext": "Brudno J.N., Kochenderfer J.N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u20133330. doi:10.1182/blood-2016-04-703751",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2016-04-703751",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Toxicities of chimeric antigen receptor T cells: recognition and management"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84977477922",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3321",
                                    "@last": "3330"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Brudno",
                                    "ce:indexed-name": "Brudno J.N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Kochenderfer",
                                    "ce:indexed-name": "Kochenderfer J.N."
                                }
                            ]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Brudno J.N., Kochenderfer J.N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u20133330. doi:10.1182/blood-2016-04-703751"
                    },
                    {
                        "ref-fulltext": "Wang X., Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. doi:10.1038/mto.2016.15",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/mto.2016.15",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical manufacturing of CAR T cells: foundation of a promising therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85006208770",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {"@first": "16015"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "X.",
                                    "@_fa": "true",
                                    "ce:surname": "Wang",
                                    "ce:indexed-name": "Wang X."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Riviere",
                                    "ce:indexed-name": "Riviere I."
                                }
                            ]},
                            "ref-sourcetitle": "Mol Ther Oncolytics"
                        },
                        "ce:source-text": "Wang X., Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. doi:10.1038/mto.2016.15"
                    },
                    {
                        "ref-fulltext": "Locke F.L., Ghobadi A., Jacobson C.A., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. doi:10.1016/S1470-2045(18)30864-7",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S1470-2045(18)30864-7",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85059501669",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "31",
                                    "@last": "42"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Locke F.L., Ghobadi A., Jacobson C.A., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. doi:10.1016/S1470-2045(18)30864-7"
                    },
                    {
                        "ref-fulltext": "Chong E.A., Ruella M., Schuster S.J., Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673\u2013674. doi:10.1056/NEJMc2030164",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMc2030164",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85101296406",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "384",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "673",
                                    "@last": "674"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Chong",
                                        "ce:indexed-name": "Chong E.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruella",
                                        "ce:indexed-name": "Ruella M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schuster",
                                        "ce:indexed-name": "Schuster S.J."
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "1",
                                    "ce:text": "Lymphoma Program Investigators at the University of Pennsylvania",
                                    "ce:indexed-name": "Lymphoma Program Investigators at the University of Pennsylvania"
                                }
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Chong E.A., Ruella M., Schuster S.J., Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673\u2013674. doi:10.1056/NEJMc2030164"
                    },
                    {
                        "ref-fulltext": "Abramson J.S., Palomba M.L., Gordon L.I., et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019; 134(Supplement_1):241. doi:10.1182/blood-2019-127508",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2019-127508",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85079068010",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "241"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Gordon",
                                        "ce:indexed-name": "Gordon L.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Abramson J.S., Palomba M.L., Gordon L.I., et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019; 134(Supplement_1):241. doi:10.1182/blood-2019-127508"
                    },
                    {
                        "ref-fulltext": "Locke F.L., Miklos D.B., Jacobson C., et al. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) vs standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma. Blood. 2021;138(Supplement 1):2. doi:10.1182/blood-2021-148039",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2021-148039",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) vs standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85127041890",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "138"},
                                "pagerange": {"@first": "2"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Miklos",
                                        "ce:indexed-name": "Miklos D.B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Locke F.L., Miklos D.B., Jacobson C., et al. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) vs standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma. Blood. 2021;138(Supplement 1):2. doi:10.1182/blood-2021-148039"
                    },
                    {
                        "ref-fulltext": "Kamdar M., Solomon S.R., Arnason J.E., et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement 1):91. doi:10.1182/blood-2021-147913",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2021-147913",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85125487873",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "138"},
                                "pagerange": {"@first": "91"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kamdar",
                                        "ce:indexed-name": "Kamdar M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Solomon",
                                        "ce:indexed-name": "Solomon S.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Arnason",
                                        "ce:indexed-name": "Arnason J.E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Kamdar M., Solomon S.R., Arnason J.E., et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement 1):91. doi:10.1182/blood-2021-147913"
                    },
                    {
                        "ref-fulltext": "Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u2013448. doi:10.1056/NEJMoa1709866",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1709866",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85041428116",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "439",
                                    "@last": "448"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Maude",
                                        "ce:indexed-name": "Maude S.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Laetsch",
                                        "ce:indexed-name": "Laetsch T.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Buechner",
                                        "ce:indexed-name": "Buechner J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u2013448. doi:10.1056/NEJMoa1709866"
                    },
                    {
                        "ref-fulltext": "Park J.H., Riviere I., Gonen M., et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u2013459. doi:10.1056/NEJMoa1709919",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1709919",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85041377767",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "449",
                                    "@last": "459"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gonen",
                                        "ce:indexed-name": "Gonen M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Park J.H., Riviere I., Gonen M., et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u2013459. doi:10.1056/NEJMoa1709919"
                    },
                    {
                        "ref-fulltext": "Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u2013528. doi:10.1016/S0140-6736(14)61403-3",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S0140-6736(14)61403-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84923019006",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "385",
                                    "@issue": "9967"
                                },
                                "pagerange": {
                                    "@first": "517",
                                    "@last": "528"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stetler-Stevenson",
                                        "ce:indexed-name": "Stetler-Stevenson M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet."
                        },
                        "ce:source-text": "Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u2013528. doi:10.1016/S0140-6736(14)61403-3"
                    },
                    {
                        "ref-fulltext": "Shah B.D., Bishop M.R., Oluwole O.O., et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322. doi:10.1182/blood.2020009098",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood.2020009098",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85109442471",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "138",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "11",
                                    "@last": "22"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah B.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "O.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole O.O."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Shah B.D., Bishop M.R., Oluwole O.O., et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322. doi:10.1182/blood.2020009098"
                    },
                    {
                        "ref-fulltext": "Romero D. KTE-X19 active in MCL. Nat Rev Clin Oncol. 2020;17(6):336. doi:10.1038/s41571-020-0373-3",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41571-020-0373-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "KTE-X19 active in MCL"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083771499",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "17",
                                    "@issue": "6"
                                },
                                "pagerange": {"@first": "336"}
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "D.",
                                "@_fa": "true",
                                "ce:surname": "Romero",
                                "ce:indexed-name": "Romero D."
                            }]},
                            "ref-sourcetitle": "Nat Rev Clin Oncol"
                        },
                        "ce:source-text": "Romero D. KTE-X19 active in MCL. Nat Rev Clin Oncol. 2020;17(6):336. doi:10.1038/s41571-020-0373-3"
                    },
                    {
                        "ref-fulltext": "Turtle C.J., Hay K.A., Hanafi L.A., et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u20133020. doi:10.1200/JCO.2017.72.8519",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2017.72.8519",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85029155281",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3010",
                                    "@last": "3020"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Turtle C.J., Hay K.A., Hanafi L.A., et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u20133020. doi:10.1200/JCO.2017.72.8519"
                    },
                    {
                        "ref-fulltext": "Porter D.L., Hwang W.T., Frey N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi:10.1126/scitranslmed.aac5415",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1126/scitranslmed.aac5415",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84940881287",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {
                                "@volume": "7",
                                "@issue": "303"
                            }},
                            "ref-text": "303ra139",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Hwang",
                                        "ce:indexed-name": "Hwang W.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Frey",
                                        "ce:indexed-name": "Frey N.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Porter D.L., Hwang W.T., Frey N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi:10.1126/scitranslmed.aac5415"
                    },
                    {
                        "ref-fulltext": "Geyer M.B., Riviere I., Senechal B., et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019;5 doi:10.1172/jci.insight.122627",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1172/jci.insight.122627",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85067610952",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {"@volume": "5"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Geyer",
                                        "ce:indexed-name": "Geyer M.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Senechal",
                                        "ce:indexed-name": "Senechal B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JCI Insight"
                        },
                        "ce:source-text": "Geyer M.B., Riviere I., Senechal B., et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019;5 doi:10.1172/jci.insight.122627"
                    },
                    {
                        "ref-fulltext": "Locke F.L., Rossi J.M., Neelapu S.S., et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u20134911. doi:10.1182/bloodadvances.2020002394",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020002394",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85095741006",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "4898",
                                    "@last": "4911"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Rossi",
                                        "ce:indexed-name": "Rossi J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Locke F.L., Rossi J.M., Neelapu S.S., et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u20134911. doi:10.1182/bloodadvances.2020002394"
                    },
                    {
                        "ref-fulltext": "Nastoupil L.J., Jain M.D., Feng L., et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119\u20133128. doi:10.1200/JCO.19.02104",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.19.02104",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85086804860",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "27"
                                },
                                "pagerange": {
                                    "@first": "3119",
                                    "@last": "3128"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Nastoupil",
                                        "ce:indexed-name": "Nastoupil L.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain M.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Feng",
                                        "ce:indexed-name": "Feng L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Nastoupil L.J., Jain M.D., Feng L., et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119\u20133128. doi:10.1200/JCO.19.02104"
                    },
                    {
                        "ref-fulltext": "Pasquini M.C., Hu Z.H., Curran K., et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u20135424. doi:10.1182/bloodadvances.2020003092",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020003092",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85096931359",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "21"
                                },
                                "pagerange": {
                                    "@first": "5414",
                                    "@last": "5424"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Pasquini",
                                        "ce:indexed-name": "Pasquini M.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu Z.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Curran",
                                        "ce:indexed-name": "Curran K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pasquini M.C., Hu Z.H., Curran K., et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414\u20135424. doi:10.1182/bloodadvances.2020003092"
                    },
                    {
                        "ref-fulltext": "Iacoboni G., Iraola-Truchuelo J., Martinez-Cibrian N., et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Blood. 2020;136(Supplement 1):19\u201321. doi:10.1182/blood-2020-136201",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2020-136201",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85104291064",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "136"},
                                "pagerange": {
                                    "@first": "19",
                                    "@last": "21"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Iacoboni",
                                        "ce:indexed-name": "Iacoboni G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Iraola-Truchuelo",
                                        "ce:indexed-name": "Iraola-Truchuelo J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Martinez-Cibrian",
                                        "ce:indexed-name": "Martinez-Cibrian N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Iacoboni G., Iraola-Truchuelo J., Martinez-Cibrian N., et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Blood. 2020;136(Supplement 1):19\u201321. doi:10.1182/blood-2020-136201"
                    },
                    {
                        "ref-fulltext": "Teachey D.T., Lacey S.F., Shaw P.A., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u2013679. doi:10.1158/2159-8290.CD-16-0040",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1158/2159-8290.CD-16-0040",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85011955241",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "664",
                                    "@last": "679"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Teachey",
                                        "ce:indexed-name": "Teachey D.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw P.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Teachey D.T., Lacey S.F., Shaw P.A., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u2013679. doi:10.1158/2159-8290.CD-16-0040"
                    },
                    {
                        "ref-fulltext": "Giavridis T., van der Stegen S.J.C., Eyquem J., Hamieh M., Piersigilli A., Sadelain M.C.A.R. T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u2013738. doi:10.1038/s41591-018-0041-7",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41591-018-0041-7",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85047803079",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "731",
                                    "@last": "738"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Giavridis",
                                    "ce:indexed-name": "Giavridis T."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.J.C.",
                                    "@_fa": "true",
                                    "ce:surname": "van der Stegen",
                                    "ce:indexed-name": "van der Stegen S.J.C."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Eyquem",
                                    "ce:indexed-name": "Eyquem J."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Hamieh",
                                    "ce:indexed-name": "Hamieh M."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Piersigilli",
                                    "ce:indexed-name": "Piersigilli A."
                                },
                                {
                                    "@seq": "6",
                                    "ce:initials": "M.C.A.R.",
                                    "@_fa": "true",
                                    "ce:surname": "Sadelain",
                                    "ce:indexed-name": "Sadelain M.C.A.R."
                                }
                            ]},
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Giavridis T., van der Stegen S.J.C., Eyquem J., Hamieh M., Piersigilli A., Sadelain M.C.A.R. T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u2013738. doi:10.1038/s41591-018-0041-7"
                    },
                    {
                        "ref-fulltext": "Lee D.W., Santomasso B.D., Locke F.L., et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u2013638. doi:10.1016/j.bbmt.2018.12.758",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.bbmt.2018.12.758",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062342961",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "625",
                                    "@last": "638"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transpl"
                        },
                        "ce:source-text": "Lee D.W., Santomasso B.D., Locke F.L., et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u2013638. doi:10.1016/j.bbmt.2018.12.758"
                    },
                    {
                        "ref-fulltext": "Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u2013733. doi:10.1056/NEJMoa1103849",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMoa1103849",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "80051720194",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "365",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "725",
                                    "@last": "733"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "D.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Porter",
                                    "ce:indexed-name": "Porter D.L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "B.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Levine",
                                    "ce:indexed-name": "Levine B.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Kalos",
                                    "ce:indexed-name": "Kalos M."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Bagg",
                                    "ce:indexed-name": "Bagg A."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "C.H.",
                                    "@_fa": "true",
                                    "ce:surname": "June",
                                    "ce:indexed-name": "June C.H."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u2013733. doi:10.1056/NEJMoa1103849"
                    },
                    {
                        "ref-fulltext": "Pennisi M., Jain T., Santomasso B.D., et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676\u2013686. doi:10.1182/bloodadvances.2019000952",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2019000952",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082179456",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "676",
                                    "@last": "686"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pennisi M., Jain T., Santomasso B.D., et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676\u2013686. doi:10.1182/bloodadvances.2019000952"
                    },
                    {
                        "ref-fulltext": "Yakoub-Agha I., Chabannon C., Bader P., et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316. doi:10.3324/haematol.2019.229781",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.3324/haematol.2019.229781",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85078868386",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "105",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "297",
                                    "@last": "316"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Yakoub-Agha",
                                        "ce:indexed-name": "Yakoub-Agha I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chabannon",
                                        "ce:indexed-name": "Chabannon C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Bader",
                                        "ce:indexed-name": "Bader P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica."
                        },
                        "ce:source-text": "Yakoub-Agha I., Chabannon C., Bader P., et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316. doi:10.3324/haematol.2019.229781"
                    },
                    {
                        "ref-fulltext": "Yáñez LA-O, Alarcón A, Sánchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 4, e000746. doi:10.1136/esmoopen-2020-000746",
                        "@id": "35",
                        "ref-info": {
                            "ref-title": {"ref-titletext": "How I treat adverse effects of CAR-T cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85089924833",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "4"},
                                "pagerange": {"@first": "000746"}
                            },
                            "ref-text": "doi:10.1136/esmoopen-2020-000746",
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.A.-O.",
                                    "@_fa": "true",
                                    "ce:surname": "Yáñez",
                                    "ce:indexed-name": "Yanez L.A.-O."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Alarcón",
                                    "ce:indexed-name": "Alarcon A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Sánchez-Escamilla",
                                    "ce:indexed-name": "Sanchez-Escamilla M."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "M.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Perales",
                                    "ce:indexed-name": "Perales M.A."
                                }
                            ]},
                            "ref-sourcetitle": "ESMO Open."
                        },
                        "ce:source-text": "Yáñez LA-O, Alarcón A, Sánchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 4, e000746. doi:10.1136/esmoopen-2020-000746"
                    },
                    {
                        "ref-fulltext": "Neelapu S.S., Tummala S., Kebriaei P., et al. Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. doi:10.1038/nrclinonc.2017.148",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/nrclinonc.2017.148",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85038265543",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "15",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "47",
                                    "@last": "62"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tummala",
                                        "ce:indexed-name": "Tummala S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Kebriaei",
                                        "ce:indexed-name": "Kebriaei P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Clin Oncol"
                        },
                        "ce:source-text": "Neelapu S.S., Tummala S., Kebriaei P., et al. Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. doi:10.1038/nrclinonc.2017.148"
                    },
                    {
                        "ref-fulltext": "Brudno J.N., Kochenderfer J.N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. doi:10.1016/j.blre.2018.11.002",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.blre.2018.11.002",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85057760886",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "34"},
                                "pagerange": {
                                    "@first": "45",
                                    "@last": "55"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Brudno",
                                    "ce:indexed-name": "Brudno J.N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Kochenderfer",
                                    "ce:indexed-name": "Kochenderfer J.N."
                                }
                            ]},
                            "ref-sourcetitle": "Blood Rev"
                        },
                        "ce:source-text": "Brudno J.N., Kochenderfer J.N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. doi:10.1016/j.blre.2018.11.002"
                    },
                    {
                        "ref-fulltext": "Shalabi H., Gust J., Taraseviciute A., et al. Beyond the storm \u2013 subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021;18(6):363\u2013378. doi:10.1038/s41571-020-00456-y",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41571-020-00456-y",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Beyond the storm \u2013 subacute toxicities and late effects in children receiving CAR T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85099769741",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "18",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "363",
                                    "@last": "378"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Shalabi",
                                        "ce:indexed-name": "Shalabi H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gust",
                                        "ce:indexed-name": "Gust J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Taraseviciute",
                                        "ce:indexed-name": "Taraseviciute A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Rev Clin Oncol"
                        },
                        "ce:source-text": "Shalabi H., Gust J., Taraseviciute A., et al. Beyond the storm \u2013 subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021;18(6):363\u2013378. doi:10.1038/s41571-020-00456-y"
                    },
                    {
                        "ref-fulltext": "FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) resource. Silver Spring, MD: US Food and Drug Administration; 2016.",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84975270003",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Silver Spring, MD: US Food and Drug Administration",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "FDA-NIH Biomarker Working Group",
                                "ce:indexed-name": "FDA-NIH Biomarker Working Group"
                            }},
                            "ref-sourcetitle": "BEST (Biomarkers, EndpointS, and other Tools) resource"
                        },
                        "ce:source-text": "FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) resource. Silver Spring, MD: US Food and Drug Administration; 2016."
                    },
                    {
                        "ref-fulltext": "Paczesny S., Pasquini M.C., Pavletic S.Z., et al. Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Adv. 2021;5(11):2519\u20132522. doi:10.1182/bloodadvances.2021004604",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2021004604",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85108351661",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "2519",
                                    "@last": "2522"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paczesny",
                                        "ce:indexed-name": "Paczesny S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Pasquini",
                                        "ce:indexed-name": "Pasquini M.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Pavletic",
                                        "ce:indexed-name": "Pavletic S.Z."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Paczesny S., Pasquini M.C., Pavletic S.Z., et al. Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Adv. 2021;5(11):2519\u20132522. doi:10.1182/bloodadvances.2021004604"
                    },
                    {
                        "ref-fulltext": "Gardner R.A., Finney O., Annesley C., et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u20133331. doi:10.1182/blood-2017-02-769208",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2017-02-769208",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85019806116",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "129",
                                    "@issue": "25"
                                },
                                "pagerange": {
                                    "@first": "3322",
                                    "@last": "3331"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gardner",
                                        "ce:indexed-name": "Gardner R.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "O.",
                                        "@_fa": "true",
                                        "ce:surname": "Finney",
                                        "ce:indexed-name": "Finney O."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Annesley",
                                        "ce:indexed-name": "Annesley C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gardner R.A., Finney O., Annesley C., et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u20133331. doi:10.1182/blood-2017-02-769208"
                    },
                    {
                        "ref-fulltext": "Hay K.A., Hanafi L.A., Li D., et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u20132306. doi:10.1182/blood-2017-06-793141",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2017-06-793141",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85034805472",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "130",
                                    "@issue": "21"
                                },
                                "pagerange": {
                                    "@first": "2295",
                                    "@last": "2306"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hay K.A., Hanafi L.A., Li D., et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u20132306. doi:10.1182/blood-2017-06-793141"
                    },
                    {
                        "ref-fulltext": "Santomasso B.D., Park J.H., Salloum D., et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u2013971. doi:10.1158/2159-8290.CD-17-1319",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1158/2159-8290.CD-17-1319",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85052999490",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "958",
                                    "@last": "971"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Salloum",
                                        "ce:indexed-name": "Salloum D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Santomasso B.D., Park J.H., Salloum D., et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u2013971. doi:10.1158/2159-8290.CD-17-1319"
                    },
                    {
                        "ref-fulltext": "Turtle C.J., Hanafi L.A., Berger C., et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1126/scitranslmed.aaf8621",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84988805188",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "355"
                                },
                                "pagerange": {"@first": "355ra116"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Turtle C.J., Hanafi L.A., Berger C., et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621"
                    },
                    {
                        "ref-fulltext": "Turtle C.J., Hanafi L.A., Berger C., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u20132138. doi:10.1172/JCI85309",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1172/JCI85309",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84974555520",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "126",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "2123",
                                    "@last": "2138"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Invest"
                        },
                        "ce:source-text": "Turtle C.J., Hanafi L.A., Berger C., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u20132138. doi:10.1172/JCI85309"
                    },
                    {
                        "ref-fulltext": "Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u20131419. doi:10.1158/2159-8290.CD-17-0698",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1158/2159-8290.CD-17-0698",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85037359093",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1404",
                                    "@last": "1419"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gust",
                                        "ce:indexed-name": "Gust J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Discov"
                        },
                        "ce:source-text": "Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u20131419. doi:10.1158/2159-8290.CD-17-0698"
                    },
                    {
                        "ref-fulltext": "Davila M.L., Riviere I., Wang X., et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi:10.1126/scitranslmed.3008226",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1126/scitranslmed.3008226",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84896335556",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "224"
                                },
                                "pagerange": {"@first": "224ra25"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Davila",
                                        "ce:indexed-name": "Davila M.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Davila M.L., Riviere I., Wang X., et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi:10.1126/scitranslmed.3008226"
                    },
                    {
                        "ref-fulltext": "Shah N.N., Lee D.W., Yates B., et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39(15):1650\u20131659. doi:10.1200/JCO.20.02262",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.20.02262",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85107082874",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "39",
                                    "@issue": "15"
                                },
                                "pagerange": {
                                    "@first": "1650",
                                    "@last": "1659"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Yates",
                                        "ce:indexed-name": "Yates B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Shah N.N., Lee D.W., Yates B., et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39(15):1650\u20131659. doi:10.1200/JCO.20.02262"
                    },
                    {
                        "ref-fulltext": "Jae Hong P., Isabelle R., Xiuyan W., Terence P., Michel S., Renier J.B. Impact of disease burden on long-term outcome of 19\u201328z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2016;34(15_suppl):7003. doi:10.1200/JCO.2016.34.15_suppl.7003",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2016.34.15_suppl.7003",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Impact of disease burden on long-term outcome of 19\u201328z CAR modified T cells in adult patients with relapsed B-ALL"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84992635083",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "34"},
                                "pagerange": {"@first": "7003"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Jae Hong",
                                    "ce:indexed-name": "Jae Hong P."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Isabelle",
                                    "ce:indexed-name": "Isabelle R."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "W.",
                                    "@_fa": "true",
                                    "ce:surname": "Xiuyan",
                                    "ce:indexed-name": "Xiuyan W."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "P.",
                                    "@_fa": "true",
                                    "ce:surname": "Terence",
                                    "ce:indexed-name": "Terence P."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Michel",
                                    "ce:indexed-name": "Michel S."
                                },
                                {
                                    "@seq": "6",
                                    "ce:initials": "J.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Renier",
                                    "ce:indexed-name": "Renier J.B."
                                }
                            ]},
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Jae Hong P., Isabelle R., Xiuyan W., Terence P., Michel S., Renier J.B. Impact of disease burden on long-term outcome of 19\u201328z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2016;34(15_suppl):7003. doi:10.1200/JCO.2016.34.15_suppl.7003"
                    },
                    {
                        "ref-fulltext": "Karschnia P., Jordan J.T., Forst D.A., et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u20132221. doi:10.1182/blood-2018-12-893396",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2018-12-893396",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85066875454",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "2212",
                                    "@last": "2221"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Karschnia",
                                        "ce:indexed-name": "Karschnia P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jordan",
                                        "ce:indexed-name": "Jordan J.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Forst",
                                        "ce:indexed-name": "Forst D.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Karschnia P., Jordan J.T., Forst D.A., et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u20132221. doi:10.1182/blood-2018-12-893396"
                    },
                    {
                        "ref-fulltext": "Faramand R., Jain M., Staedtke V., et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823\u20134831. doi:10.1158/1078-0432.CCR-20-1434",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1158/1078-0432.CCR-20-1434",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85092727761",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "4823",
                                    "@last": "4831"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Faramand",
                                        "ce:indexed-name": "Faramand R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Staedtke",
                                        "ce:indexed-name": "Staedtke V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Faramand R., Jain M., Staedtke V., et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823\u20134831. doi:10.1158/1078-0432.CCR-20-1434"
                    },
                    {
                        "ref-fulltext": "Deng Q., Han G., Puebla-Osorio N., et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 2020;26(12):1878\u20131887. doi:10.1038/s41591-020-1061-7",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41591-020-1061-7",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85092083293",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1878",
                                    "@last": "1887"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Deng",
                                        "ce:indexed-name": "Deng Q."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Han",
                                        "ce:indexed-name": "Han G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Puebla-Osorio",
                                        "ce:indexed-name": "Puebla-Osorio N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Deng Q., Han G., Puebla-Osorio N., et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 2020;26(12):1878\u20131887. doi:10.1038/s41591-020-1061-7"
                    },
                    {
                        "ref-fulltext": "Young H.A. Cytokine multiplex analysis. Methods Mol Biol. 2009;511:85-105. doi:10.1007/978-1-59745-447-6_4",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1007/978-1-59745-447-6_4",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cytokine multiplex analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "65549094012",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "511"},
                                "pagerange": {
                                    "@first": "85",
                                    "@last": "105"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "H.A.",
                                "@_fa": "true",
                                "ce:surname": "Young",
                                "ce:indexed-name": "Young H.A."
                            }]},
                            "ref-sourcetitle": "Methods Mol Biol"
                        },
                        "ce:source-text": "Young H.A. Cytokine multiplex analysis. Methods Mol Biol. 2009;511:85-105. doi:10.1007/978-1-59745-447-6_4"
                    },
                    {
                        "ref-fulltext": "Morris E.C., Neelapu S.S., Giavridis T., Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021;doi:10.1038/s41577-021-00547-6",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41577-021-00547-6",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85106291891",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Morris",
                                    "ce:indexed-name": "Morris E.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Neelapu",
                                    "ce:indexed-name": "Neelapu S.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Giavridis",
                                    "ce:indexed-name": "Giavridis T."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Sadelain",
                                    "ce:indexed-name": "Sadelain M."
                                }
                            ]},
                            "ref-sourcetitle": "Nat Rev Immunol"
                        },
                        "ce:source-text": "Morris E.C., Neelapu S.S., Giavridis T., Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021;doi:10.1038/s41577-021-00547-6"
                    },
                    {
                        "ref-fulltext": "Norelli M., Camisa B., Barbiera G., et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u2013748. doi:10.1038/s41591-018-0036-4",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41591-018-0036-4",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85047813147",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "739",
                                    "@last": "748"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Norelli",
                                        "ce:indexed-name": "Norelli M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Camisa",
                                        "ce:indexed-name": "Camisa B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Barbiera",
                                        "ce:indexed-name": "Barbiera G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Norelli M., Camisa B., Barbiera G., et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u2013748. doi:10.1038/s41591-018-0036-4"
                    },
                    {
                        "ref-fulltext": "Strati P., Ahmed S., Kebriaei P., et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123\u20133127. doi:10.1182/bloodadvances.2020002328",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020002328",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85090350518",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "3123",
                                    "@last": "3127"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Strati",
                                        "ce:indexed-name": "Strati P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Ahmed",
                                        "ce:indexed-name": "Ahmed S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Kebriaei",
                                        "ce:indexed-name": "Kebriaei P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Strati P., Ahmed S., Kebriaei P., et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123\u20133127. doi:10.1182/bloodadvances.2020002328"
                    },
                    {
                        "ref-fulltext": "Hu Y., Wu Z., Luo Y., et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23(13):3297\u20133306. doi:10.1158/1078-0432.CCR-16-1799",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1158/1078-0432.CCR-16-1799",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85021755863",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "23",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "3297",
                                    "@last": "3306"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Hu",
                                        "ce:indexed-name": "Hu Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Luo",
                                        "ce:indexed-name": "Luo Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Hu Y., Wu Z., Luo Y., et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23(13):3297\u20133306. doi:10.1158/1078-0432.CCR-16-1799"
                    },
                    {
                        "ref-fulltext": "Fried S., Avigdor A., Bielorai B., et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u20131650. doi:10.1038/s41409-019-0487-3",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41409-019-0487-3",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Early and late hematologic toxicity following CD19 CAR-T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062147434",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "54",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1643",
                                    "@last": "1650"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Fried",
                                        "ce:indexed-name": "Fried S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Avigdor",
                                        "ce:indexed-name": "Avigdor A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Bielorai",
                                        "ce:indexed-name": "Bielorai B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Bone Marrow Transpl"
                        },
                        "ce:source-text": "Fried S., Avigdor A., Bielorai B., et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u20131650. doi:10.1038/s41409-019-0487-3"
                    },
                    {
                        "ref-fulltext": "Jain T., Knezevic A., Pennisi M., et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u20133787. doi:10.1182/bloodadvances.2020002509",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020002509",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85090556703",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "15"
                                },
                                "pagerange": {
                                    "@first": "3776",
                                    "@last": "3787"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Knezevic",
                                        "ce:indexed-name": "Knezevic A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Jain T., Knezevic A., Pennisi M., et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u20133787. doi:10.1182/bloodadvances.2020002509"
                    },
                    {
                        "ref-fulltext": "Rejeski K., Perez Perez A., Sesques P., et al. CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;doi:10.1182/blood.2020010543",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood.2020010543",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85118697349",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Rejeski",
                                        "ce:indexed-name": "Rejeski K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Perez Perez",
                                        "ce:indexed-name": "Perez Perez A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Sesques",
                                        "ce:indexed-name": "Sesques P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Rejeski K., Perez Perez A., Sesques P., et al. CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;doi:10.1182/blood.2020010543"
                    },
                    {
                        "ref-fulltext": "Major A., Collins J., Craney C., et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma 2021;62(7):1765\u20131769. doi:10.1080/10428194.2021.1881507",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1080/10428194.2021.1881507",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85100990966",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "62",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "1765",
                                    "@last": "1769"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Major",
                                        "ce:indexed-name": "Major A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Collins",
                                        "ce:indexed-name": "Collins J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Craney",
                                        "ce:indexed-name": "Craney C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leuk Lymphoma"
                        },
                        "ce:source-text": "Major A., Collins J., Craney C., et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma 2021;62(7):1765\u20131769. doi:10.1080/10428194.2021.1881507"
                    },
                    {
                        "ref-fulltext": "Sairah A., Fateeha F., Paolo S., et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J Clin Oncol. 2020;38(15_suppl):. doi:10.1200/JCO.2020.38.15_suppl.8057",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2020.38.15_suppl.8057",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85087663319",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {"@volume": "38"}},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Sairah",
                                        "ce:indexed-name": "Sairah A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Fateeha",
                                        "ce:indexed-name": "Fateeha F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paolo",
                                        "ce:indexed-name": "Paolo S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Sairah A., Fateeha F., Paolo S., et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). J Clin Oncol. 2020;38(15_suppl):. doi:10.1200/JCO.2020.38.15_suppl.8057"
                    },
                    {
                        "ref-fulltext": "Sandler R.D., Tattersall R.S., Schoemans H., et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults: a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524. doi:10.3389/fimmu.2020.00524",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.3389/fimmu.2020.00524",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults: a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85083477448",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "524"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sandler",
                                        "ce:indexed-name": "Sandler R.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tattersall",
                                        "ce:indexed-name": "Tattersall R.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Schoemans",
                                        "ce:indexed-name": "Schoemans H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Sandler R.D., Tattersall R.S., Schoemans H., et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults: a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524. doi:10.3389/fimmu.2020.00524"
                    },
                    {
                        "ref-fulltext": "Lichtenstein D.A., Schischlik F., Shao L., et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells. Blood. 2021; doi:10.1182/blood.2021011898",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood.2021011898",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85119658059",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lichtenstein",
                                        "ce:indexed-name": "Lichtenstein D.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Schischlik",
                                        "ce:indexed-name": "Schischlik F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Shao",
                                        "ce:indexed-name": "Shao L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Lichtenstein D.A., Schischlik F., Shao L., et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells. Blood. 2021; doi:10.1182/blood.2021011898"
                    },
                    {
                        "ref-fulltext": "Luft T., Benner A., Jodele S., et al. EASIX in patients with acute graft-vs-host disease: a retrospective cohort analysis. Lancet Haematol. 2017;4(9):e414-e423. doi:10.1016/S2352-3026(17)30108-4",
                        "@id": "65",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/S2352-3026(17)30108-4",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "EASIX in patients with acute graft-vs-host disease: a retrospective cohort analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85024893839",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "414",
                                    "@last": "e423"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Luft",
                                        "ce:indexed-name": "Luft T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Benner",
                                        "ce:indexed-name": "Benner A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Jodele",
                                        "ce:indexed-name": "Jodele S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Haematol"
                        },
                        "ce:source-text": "Luft T., Benner A., Jodele S., et al. EASIX in patients with acute graft-vs-host disease: a retrospective cohort analysis. Lancet Haematol. 2017;4(9):e414-e423. doi:10.1016/S2352-3026(17)30108-4"
                    },
                    {
                        "ref-fulltext": "Pennisi M., Sanchez-Escamilla M., Flynn J.R., et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u20133406. doi:10.1182/bloodadvances.2020003885",
                        "@id": "66",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020003885",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85115339187",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "3397",
                                    "@last": "3406"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Sanchez-Escamilla",
                                        "ce:indexed-name": "Sanchez-Escamilla M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Flynn",
                                        "ce:indexed-name": "Flynn J.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pennisi M., Sanchez-Escamilla M., Flynn J.R., et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u20133406. doi:10.1182/bloodadvances.2020003885"
                    },
                    {
                        "ref-fulltext": "Greenbaum U., Strati P., Saliba R.M., et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799\u20132806. doi:10.1182/bloodadvances.2021004575",
                        "@id": "67",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2021004575",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85111191843",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "2799",
                                    "@last": "2806"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Greenbaum",
                                        "ce:indexed-name": "Greenbaum U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Strati",
                                        "ce:indexed-name": "Strati P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Saliba",
                                        "ce:indexed-name": "Saliba R.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Greenbaum U., Strati P., Saliba R.M., et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799\u20132806. doi:10.1182/bloodadvances.2021004575"
                    },
                    {
                        "ref-fulltext": "Rubin D.B., Al Jarrah A., Li K., et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536\u20131542. doi:10.1001/jamaneurol.2020.2703",
                        "@id": "68",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1001/jamaneurol.2020.2703",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85089982690",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "77",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1536",
                                    "@last": "1542"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Rubin",
                                        "ce:indexed-name": "Rubin D.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Al Jarrah",
                                        "ce:indexed-name": "Al Jarrah A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA Neurol"
                        },
                        "ce:source-text": "Rubin D.B., Al Jarrah A., Li K., et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536\u20131542. doi:10.1001/jamaneurol.2020.2703"
                    },
                    {
                        "ref-fulltext": "Kochenderfer J.N., Somerville R.P.T., Lu T., et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u20131813. doi:10.1200/JCO.2016.71.3024",
                        "@id": "69",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2016.71.3024",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85017643829",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "1803",
                                    "@last": "1813"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.P.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Somerville",
                                        "ce:indexed-name": "Somerville R.P.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kochenderfer J.N., Somerville R.P.T., Lu T., et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u20131813. doi:10.1200/JCO.2016.71.3024"
                    },
                    {
                        "ref-fulltext": "Gauthier J., Chou C., Hirayama A.V., et al. High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics. Blood. 2020;136(Supplement 1):37\u201338. doi:10.1182/blood-2020-140120",
                        "@id": "70",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2020-140120",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85104083910",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "136"},
                                "pagerange": {
                                    "@first": "37",
                                    "@last": "38"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chou",
                                        "ce:indexed-name": "Chou C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gauthier J., Chou C., Hirayama A.V., et al. High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics. Blood. 2020;136(Supplement 1):37\u201338. doi:10.1182/blood-2020-140120"
                    },
                    {
                        "ref-fulltext": "Hirayama A.V., Gauthier J., Hay K.A., et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u20131887. doi:10.1182/blood-2018-11-887067",
                        "@id": "71",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2018-11-887067",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85065170101",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1876",
                                    "@last": "1887"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hirayama A.V., Gauthier J., Hay K.A., et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u20131887. doi:10.1182/blood-2018-11-887067"
                    },
                    {
                        "ref-fulltext": "Fraietta J.A., Lacey S.F., Orlando E.J., et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u2013571. doi:10.1038/s41591-018-0010-1",
                        "@id": "72",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41591-018-0010-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85046093409",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "563",
                                    "@last": "571"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Orlando",
                                        "ce:indexed-name": "Orlando E.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Fraietta J.A., Lacey S.F., Orlando E.J., et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u2013571. doi:10.1038/s41591-018-0010-1"
                    },
                    {
                        "ref-fulltext": "Hay K.A., Gauthier J., Hirayama A.V., et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u20131663. doi:10.1182/blood-2018-11-883710",
                        "@id": "73",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2018-11-883710",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85064806676",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "15"
                                },
                                "pagerange": {
                                    "@first": "1652",
                                    "@last": "1663"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hay K.A., Gauthier J., Hirayama A.V., et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u20131663. doi:10.1182/blood-2018-11-883710"
                    },
                    {
                        "ref-fulltext": "Vercellino L., Di Blasi R., Kanoun S., et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u20135615. doi:10.1182/bloodadvances.2020003001",
                        "@id": "74",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020003001",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85097238142",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "5607",
                                    "@last": "5615"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Vercellino",
                                        "ce:indexed-name": "Vercellino L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Blasi",
                                        "ce:indexed-name": "Di Blasi R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kanoun",
                                        "ce:indexed-name": "Kanoun S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Vercellino L., Di Blasi R., Kanoun S., et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u20135615. doi:10.1182/bloodadvances.2020003001"
                    },
                    {
                        "ref-fulltext": "Yang Y., Kohler M.E., Chien C.D., et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017;9(417)doi:10.1126/scitranslmed.aag1209",
                        "@id": "75",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1126/scitranslmed.aag1209",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85035020295",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {
                                "@volume": "9",
                                "@issue": "417"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Yang",
                                        "ce:indexed-name": "Yang Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Kohler",
                                        "ce:indexed-name": "Kohler M.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Chien",
                                        "ce:indexed-name": "Chien C.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Yang Y., Kohler M.E., Chien C.D., et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017;9(417)doi:10.1126/scitranslmed.aag1209"
                    },
                    {
                        "ref-fulltext": "Sommermeyer D., Hudecek M., Kosasih P.L., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500. doi:10.1038/leu.2015.247",
                        "@id": "76",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/leu.2015.247",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84959328185",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "492",
                                    "@last": "500"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sommermeyer",
                                        "ce:indexed-name": "Sommermeyer D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Hudecek",
                                        "ce:indexed-name": "Hudecek M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kosasih",
                                        "ce:indexed-name": "Kosasih P.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Sommermeyer D., Hudecek M., Kosasih P.L., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500. doi:10.1038/leu.2015.247"
                    },
                    {
                        "ref-fulltext": "Garfall A.L., Dancy E.K., Cohen A.D., et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812\u20132815. doi:10.1182/bloodadvances.2019000600",
                        "@id": "77",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2019000600",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85073423205",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "2812",
                                    "@last": "2815"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Garfall",
                                        "ce:indexed-name": "Garfall A.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Dancy",
                                        "ce:indexed-name": "Dancy E.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen A.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Garfall A.L., Dancy E.K., Cohen A.D., et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812\u20132815. doi:10.1182/bloodadvances.2019000600"
                    },
                    {
                        "ref-fulltext": "Beider K., Besser M.J., Schachter J., et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies. Blood. 2019;134(Supplement_1):3234. doi:10.1182/blood-2019-128068",
                        "@id": "78",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2019-128068",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084973048",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "3234"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Beider",
                                        "ce:indexed-name": "Beider K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Besser",
                                        "ce:indexed-name": "Besser M.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schachter",
                                        "ce:indexed-name": "Schachter J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Beider K., Besser M.J., Schachter J., et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies. Blood. 2019;134(Supplement_1):3234. doi:10.1182/blood-2019-128068"
                    },
                    {
                        "ref-fulltext": "Mailankody S., Jakubowiak A.J., Htut M., et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15):8504. doi:10.1200/JCO.2020.38.15_suppl.8504",
                        "@id": "79",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.2020.38.15_suppl.8504",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85103975741",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "8504"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Mailankody",
                                        "ce:indexed-name": "Mailankody S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Jakubowiak",
                                        "ce:indexed-name": "Jakubowiak A.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Htut",
                                        "ce:indexed-name": "Htut M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Mailankody S., Jakubowiak A.J., Htut M., et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15):8504. doi:10.1200/JCO.2020.38.15_suppl.8504"
                    },
                    {
                        "ref-fulltext": "Shah N.N., Highfill S.L., Shalabi H., et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol 2020;38(17):1938\u20131950. doi:10.1200/jco.19.03279",
                        "@id": "80",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/jco.19.03279",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85084220891",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1938",
                                    "@last": "1950"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Highfill",
                                        "ce:indexed-name": "Highfill S.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Shalabi",
                                        "ce:indexed-name": "Shalabi H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Shah N.N., Highfill S.L., Shalabi H., et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol 2020;38(17):1938\u20131950. doi:10.1200/jco.19.03279"
                    },
                    {
                        "ref-fulltext": "Bachanova V., Tam C.S., Borchmann P., et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Blood. 2019;134(Supplement_1):242. doi:10.1182/blood-2019-128302",
                        "@id": "81",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2019-128302",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85085767361",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "242"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Bachanova",
                                        "ce:indexed-name": "Bachanova V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Borchmann",
                                        "ce:indexed-name": "Borchmann P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood."
                        },
                        "ce:source-text": "Bachanova V., Tam C.S., Borchmann P., et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Blood. 2019;134(Supplement_1):242. doi:10.1182/blood-2019-128302"
                    },
                    {
                        "ref-fulltext": "Rossi J., Paczkowski P., Shen Y.W., et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u2013814. doi:10.1182/blood-2018-01-828343",
                        "@id": "82",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2018-01-828343",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85052110726",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "132",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "804",
                                    "@last": "814"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Rossi",
                                        "ce:indexed-name": "Rossi J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Paczkowski",
                                        "ce:indexed-name": "Paczkowski P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Shen",
                                        "ce:indexed-name": "Shen Y.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Rossi J., Paczkowski P., Shen Y.W., et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u2013814. doi:10.1182/blood-2018-01-828343"
                    },
                    {
                        "ref-fulltext": "Xue Q., Bettini E., Paczkowski P., et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. J Immunother Cancer. 2017;5(1):85. doi:10.1186/s40425-017-0293-7",
                        "@id": "83",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1186/s40425-017-0293-7",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85034584087",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "85"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Xue",
                                        "ce:indexed-name": "Xue Q."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Bettini",
                                        "ce:indexed-name": "Bettini E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Paczkowski",
                                        "ce:indexed-name": "Paczkowski P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Xue Q., Bettini E., Paczkowski P., et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. J Immunother Cancer. 2017;5(1):85. doi:10.1186/s40425-017-0293-7"
                    },
                    {
                        "ref-fulltext": "Zhou C.B., Zhou Y.L., Fang J.Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer 2021;7(7):647\u2013660. doi:10.1016/j.trecan.2021.01.010",
                        "@id": "84",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.trecan.2021.01.010",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Gut microbiota in cancer immune response and immunotherapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85101871737",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "647",
                                    "@last": "660"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "C.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Zhou",
                                    "ce:indexed-name": "Zhou C.B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Y.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Zhou",
                                    "ce:indexed-name": "Zhou Y.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "J.Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Fang",
                                    "ce:indexed-name": "Fang J.Y."
                                }
                            ]},
                            "ref-sourcetitle": "Trends Cancer"
                        },
                        "ce:source-text": "Zhou C.B., Zhou Y.L., Fang J.Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer 2021;7(7):647\u2013660. doi:10.1016/j.trecan.2021.01.010"
                    },
                    {
                        "ref-fulltext": "Smith M., Littmann E., Slingerland J., et al. Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy. Biol Blood Marrow Transplant. 2019;25(3):S177. doi:https://doi.org/10.1016/j.bbmt.2018.12.319",
                        "@id": "85",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.bbmt.2018.12.319",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85075843190",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "S177"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Littmann",
                                        "ce:indexed-name": "Littmann E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Slingerland",
                                        "ce:indexed-name": "Slingerland J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Smith M., Littmann E., Slingerland J., et al. Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy. Biol Blood Marrow Transplant. 2019;25(3):S177. doi:https://doi.org/10.1016/j.bbmt.2018.12.319"
                    },
                    {
                        "ref-fulltext": "Lindo L., Wilkinson L.H., Hay K.A. Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol. 2020;11:618387. doi:10.3389/fimmu.2020.618387",
                        "@id": "86",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.3389/fimmu.2020.618387",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Befriending the hostile tumor microenvironment in CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85101622578",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {"@first": "618387"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Lindo",
                                    "ce:indexed-name": "Lindo L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Wilkinson",
                                    "ce:indexed-name": "Wilkinson L.H."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "K.A.",
                                    "@_fa": "true",
                                    "ce:surname": "Hay",
                                    "ce:indexed-name": "Hay K.A."
                                }
                            ]},
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Lindo L., Wilkinson L.H., Hay K.A. Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol. 2020;11:618387. doi:10.3389/fimmu.2020.618387"
                    },
                    {
                        "ref-fulltext": "Scarfo I., Maus M.V. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5:28. doi:10.1186/s40425-017-0230-9",
                        "@id": "87",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1186/s40425-017-0230-9",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85015649083",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {"@first": "28"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Scarfo",
                                    "ce:indexed-name": "Scarfo I."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.V.",
                                    "@_fa": "true",
                                    "ce:surname": "Maus",
                                    "ce:indexed-name": "Maus M.V."
                                }
                            ]},
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Scarfo I., Maus M.V. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5:28. doi:10.1186/s40425-017-0230-9"
                    },
                    {
                        "ref-fulltext": "Reiss D.J., Do T., Kuo D., et al. Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response. Blood. 2019;134(Supplement_1):202. doi:10.1182/blood-2019-127683",
                        "@id": "88",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2019-127683",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85087009032",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "202"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Reiss",
                                        "ce:indexed-name": "Reiss D.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Do",
                                        "ce:indexed-name": "Do T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuo",
                                        "ce:indexed-name": "Kuo D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Reiss D.J., Do T., Kuo D., et al. Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response. Blood. 2019;134(Supplement_1):202. doi:10.1182/blood-2019-127683"
                    },
                    {
                        "ref-fulltext": "Mancikova V., Peschelova H., Kozlova V., et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J Immunother Cancer. 2020;8(1) doi:10.1136/jitc-2019-000471",
                        "@id": "89",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1136/jitc-2019-000471",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082561679",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {"voliss": {
                                "@volume": "8",
                                "@issue": "1"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Mancikova",
                                        "ce:indexed-name": "Mancikova V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Peschelova",
                                        "ce:indexed-name": "Peschelova H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Kozlova",
                                        "ce:indexed-name": "Kozlova V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Mancikova V., Peschelova H., Kozlova V., et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J Immunother Cancer. 2020;8(1) doi:10.1136/jitc-2019-000471"
                    },
                    {
                        "ref-fulltext": "Shouval R., Alarcon Tomas A., Fein J.A., et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J Clin Oncol. 2021:JCO2102143. doi:10.1200/JCO.21.02143",
                        "@id": "90",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1200/JCO.21.02143",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85123901457",
                                "@idtype": "SGR"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Shouval",
                                        "ce:indexed-name": "Shouval R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Alarcon Tomas",
                                        "ce:indexed-name": "Alarcon Tomas A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fein",
                                        "ce:indexed-name": "Fein J.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Shouval R., Alarcon Tomas A., Fein J.A., et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J Clin Oncol. 2021:JCO2102143. doi:10.1200/JCO.21.02143"
                    },
                    {
                        "ref-fulltext": "Li L., Liu J., Xu M., et al. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. Cell Death Dis. 2020;11(3):207. doi:10.1038/s41419-020-2388-1",
                        "@id": "91",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1038/s41419-020-2388-1",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082730025",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "207"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cell Death Dis"
                        },
                        "ce:source-text": "Li L., Liu J., Xu M., et al. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. Cell Death Dis. 2020;11(3):207. doi:10.1038/s41419-020-2388-1"
                    },
                    {
                        "ref-fulltext": "Shah N.N., Nagle S.J., Torigian D.A., et al. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018;20(12):1415\u20131418. doi:10.1016/j.jcyt.2018.10.003",
                        "@id": "92",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.jcyt.2018.10.003",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85057563885",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1415",
                                    "@last": "1418"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Nagle",
                                        "ce:indexed-name": "Nagle S.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Torigian",
                                        "ce:indexed-name": "Torigian D.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cytotherapy"
                        },
                        "ce:source-text": "Shah N.N., Nagle S.J., Torigian D.A., et al. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018;20(12):1415\u20131418. doi:10.1016/j.jcyt.2018.10.003"
                    },
                    {
                        "ref-fulltext": "Dean E.A., Mhaskar R.S., Lu H., et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268\u20133276. doi:10.1182/bloodadvances.2020001900",
                        "@id": "93",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/bloodadvances.2020001900",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85090452202",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "3268",
                                    "@last": "3276"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Dean",
                                        "ce:indexed-name": "Dean E.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Mhaskar",
                                        "ce:indexed-name": "Mhaskar R.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Dean E.A., Mhaskar R.S., Lu H., et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268\u20133276. doi:10.1182/bloodadvances.2020001900"
                    },
                    {
                        "ref-fulltext": "Sesques P., Tordo J., Ferrant E., et al. Prognostic impact of 18F-FDG PET/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med. 2021;46(8):627\u2013634. doi:10.1097/RLU.0000000000003756",
                        "@id": "94",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1097/RLU.0000000000003756",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Prognostic impact of 18F-FDG PET/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85110574483",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "46",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "627",
                                    "@last": "634"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Sesques",
                                        "ce:indexed-name": "Sesques P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Tordo",
                                        "ce:indexed-name": "Tordo J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Ferrant",
                                        "ce:indexed-name": "Ferrant E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Nucl Med"
                        },
                        "ce:source-text": "Sesques P., Tordo J., Ferrant E., et al. Prognostic impact of 18F-FDG PET/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med. 2021;46(8):627\u2013634. doi:10.1097/RLU.0000000000003756"
                    },
                    {
                        "ref-fulltext": "Jacobson C.A., Hunter B., Armand P., et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Supplement 1):92. doi:10.1182/blood-2018-99-117199",
                        "@id": "95",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1182/blood-2018-99-117199",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85065099140",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "132"},
                                "pagerange": {"@first": "92"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Hunter",
                                        "ce:indexed-name": "Hunter B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Armand",
                                        "ce:indexed-name": "Armand P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Jacobson C.A., Hunter B., Armand P., et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Supplement 1):92. doi:10.1182/blood-2018-99-117199"
                    },
                    {
                        "ref-fulltext": "Neelapu S.S., Locke F.L., Go W.Y. CAR T-cell therapy in large B-cell lymphoma. N Engl J Med. 2018;378(11):1065. doi:10.1056/NEJMc1800913",
                        "@id": "96",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1056/NEJMc1800913",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "CAR T-cell therapy in large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85044241496",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "11"
                                },
                                "pagerange": {"@first": "1065"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Neelapu",
                                    "ce:indexed-name": "Neelapu S.S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "F.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Locke",
                                    "ce:indexed-name": "Locke F.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "W.Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Go",
                                    "ce:indexed-name": "Go W.Y."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Neelapu S.S., Locke F.L., Go W.Y. CAR T-cell therapy in large B-cell lymphoma. N Engl J Med. 2018;378(11):1065. doi:10.1056/NEJMc1800913"
                    },
                    {
                        "ref-fulltext": "Garcia-Recio M., Wudhikarn K., Pennisi M., et al. The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2021;27(3):233\u2013240. doi:10.1016/j.jtct.2020.10.022",
                        "@id": "97",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://doi.org/10.1016/j.jtct.2020.10.022",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85101145531",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "27",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "233",
                                    "@last": "240"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Garcia-Recio",
                                        "ce:indexed-name": "Garcia-Recio M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wudhikarn",
                                        "ce:indexed-name": "Wudhikarn K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Pennisi",
                                        "ce:indexed-name": "Pennisi M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Transpl Cell Ther"
                        },
                        "ce:source-text": "Garcia-Recio M., Wudhikarn K., Pennisi M., et al. The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2021;27(3):233\u2013240. doi:10.1016/j.jtct.2020.10.022"
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Murcia",
            "@id": "60000130",
            "affilname": "Universidad de Murcia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000130",
            "affiliation-country": "Spain"
        }
    ],
    "coredata": {
        "srctype": "b",
        "eid": "2-s2.0-85137915823",
        "dc:description": "Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment armamentarium of relapsed/refractory hematologic malignancies, enabling high response rates, and potential cure. Despite these impressive antitumor effects, many patients experience relapse or fail to respond after receiving CAR T cells. There are also several unique side effects associated with morbidity and mortality, including immune-mediated phenomena, prolonged cytopenias, B-cell aplasia, and hypogammaglobulinemia. Several studies have explored predictive biomarkers to identify patients at risk of treatment failure or adverse events. A biomarker-based approach to CAR T-cell treatment may improve patient selection by identifying risk factors for nonresponders and for severe toxicities, as well as help researchers identify targets for novel CAR T-cell products.",
        "prism:coverDate": "2022-01-01",
        "prism:aggregationType": "Book",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85137915823",
        "subtypeDescription": "Book Chapter",
        "dc:creator": {"author": [{
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85137915823"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137915823&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85137915823&origin=inward"
            }
        ],
        "prism:isbn": [
            {"$": "9780128243022"},
            {"$": "9780128243039"}
        ],
        "prism:publicationName": "Cancer Biomarkers: Clinical Aspects and Laboratory Determination",
        "source-id": "21101107507",
        "citedby-count": "0",
        "subtype": "ch",
        "prism:pageRange": "245-281",
        "dc:title": "Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers",
        "prism:endingPage": "281",
        "openaccess": "0",
        "openaccessFlag": "false",
        "prism:doi": "10.1016/B978-0-12-824302-2.00012-6",
        "prism:startingPage": "245",
        "publishercopyright": "© 2022 Elsevier Inc. All rights reserved.",
        "dc:identifier": "SCOPUS_ID:85137915823",
        "dc:publisher": "Elsevier"
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "Biomarkers"
        },
        {
            "@_fa": "true",
            "$": "CAR T cell"
        },
        {
            "@_fa": "true",
            "$": "chimeric antigen receptor T cell"
        },
        {
            "@_fa": "true",
            "$": "hematologic malignancy"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Agricultural and Biological Sciences (all)",
            "@code": "1100",
            "@abbrev": "AGRI"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry, Genetics and Molecular Biology (all)",
            "@code": "1300",
            "@abbrev": "BIOC"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        },
        {
            "ce:given-name": "Ana Alarcón",
            "preferred-name": {
                "ce:given-name": "Ana Alarcón",
                "ce:initials": "A.A.",
                "ce:surname": "Tomás",
                "ce:indexed-name": "Tomás A.A."
            },
            "@seq": "2",
            "ce:initials": "A.A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60000130",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000130"
                }
            ],
            "ce:surname": "Tomás",
            "@auid": "57216155516",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216155516",
            "ce:indexed-name": "Tomas A.A."
        },
        {
            "ce:given-name": "Miguel-Angel",
            "preferred-name": {
                "ce:given-name": "Miguel Angel",
                "ce:initials": "M.A.",
                "ce:surname": "Perales",
                "ce:indexed-name": "Perales M.A."
            },
            "@seq": "3",
            "ce:initials": "M.-A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Perales",
            "@auid": "6701893624",
            "author-url": "https://api.elsevier.com/content/author/author_id/6701893624",
            "ce:indexed-name": "Perales M.-A."
        },
        {
            "ce:given-name": "Kazunori",
            "preferred-name": {
                "ce:given-name": "Kazunori",
                "ce:initials": "K.",
                "ce:surname": "Murata",
                "ce:indexed-name": "Murata K."
            },
            "@seq": "4",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "Murata",
            "@auid": "7403723230",
            "author-url": "https://api.elsevier.com/content/author/author_id/7403723230",
            "ce:indexed-name": "Murata K."
        }
    ]}
}}